Efficacy of 5a-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia
- Authors: Nizov A.N1
-
Affiliations:
- Roswell Park Comprehensive Medical Center
- Issue: No 5 (2019)
- Pages: 156-160
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312329
- DOI: https://doi.org/10.18565/urology.2019.5.156-160
- ID: 312329
Cite item
Open Access
Access granted
Abstract
In the treatment of lower urinary tract in combination with benign prostatic hyperplasia, alpha-blockers are most often prescribed, but in certain cases, the appointment of 5a-reductase inhibitors is justified. This article analyzes relevant studies of recent years regarding the validity of the use of dutasteride (Gardium) 0.5 mg per day. Dutasteride can effectively reduce the total score of IPSS to 30%. It increases a volumetric urine flow rate 2-3 ml/sec, significantly reduces the chance of acute urinary retention in 70-88% in various studies, and reduces the frequency of hospitalization by 66%. Dutasteride also increases the likelihood of timely diagnosis of prostate cancer by 23%. Erectile dysfunction is a common side effect, serving as a reason for refusal of therapy is erectile dysfunction, which occurs in 16% of cases, and the probability of which is the highest in the first months during conservative therapy.
Full Text
About the authors
A. N Nizov
Roswell Park Comprehensive Medical Center
Email: nizovale@gmail.com
MD, PhD, research fellow
References
- Snyder P.J. 5-alpha reductase inhibitors. Androgens. In, Brunton L.L., Chabner B.A., Knollman B.C. Goodman & Gilman’s The pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011. Р 1205.
- Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Yang H., Rochon J.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135: 1924-1934.
- Urology: Russian Clinical Recommendations / edited by Y.G. Alyev, Y.V. Glybochko, Pushkar D.Y. 2017. 544 p.
- Alpha Reductase Inhibitors. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-2018 Jan 9.
- Naslund M.J., Miner M. A review of the clinical efficacy and safety of 5 alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29:17-25.
- Kawahara T. Editorial Comment to Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia. Int J Urol. 2018;25(11):951-952. doi: 10.1111/iju.13798.
- Roehrborn C.G., Siami P., Barkin J., Damiao R., Major Walker K., Nandy I., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 year results from the CombAT study. Eur Urol 2010;57:123-131.
- Saito M., Shimizu S., Kinoshita Y., Satoh I., Shomori K., Dimitriadis F., et al. Bladder dysfunction after acute urinary retention in the rats: A novel over active bladder model. Mol Cell Biochem. 2010; 333:109-114.
- Tsukamoto T., Endo Y., Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009;16:745-750.
- Iziev М.М., Al-Shukri A.S., Tkachuk V.N. The state of urodynamics of the lower urinary tract in patients with benign prostatic hyperplasia on the background of dutasteride treatment, Urologicheskii Vedomosti. 2017;7(3):28-33. doi: 10.17816/uroved7328-33.
- Cindolo L., Fanizza C., Romero M., Pirozzi L., Autorino R., Berardinelli F, Schips L. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2013;31(3):665-671. doi: 10.1007/s00345-012-1000-4.
- Fenter T.C., Davis E.A., Shah M.B., Lin P.J. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged >or=65 years. Am J Manag Care. 2008;14(5 Suppl 2):S154-159.
- Yin T., Qiao Z., Li Y., Li D., Jiang M., An C., Wang F., Zuo M., Hu K., Li Q. Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis. Am J Ther. 2017t;24(5):e517-e523. doi: 10.1097/MJT.0000000000000326.
- Hagiwara K., Koie T., Iwamura H., Imai A., Hatakeyama S., Yoneyama T., et al. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a Single arm prospective study. Biomed Res Int 2016; 2016:4975851.
- McVary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., Foster H.E., Gonzalez C. M., Kaplan S. A., Penson D.F., Ulchaker J.C., Wei J.T. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-1803.
- Tkachuk V.N., Iziev М.М. Evaluation of efficacy and safety of long-term therapy with dutasteride in patients with benign prostatic hyperplasia. Nephrologia. 2016;20(1):63-68.
- Trueb R.M., Regnier A., Dutra Rezende H., Gavazzoni Dias M.F.R. PostFinasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? Skin Appendage Disord. 2019;5(5):320- 326. doi: 10.1159/000497362.
- Monga N., Sayani A., Rubinger D.A., Wilson T.H., Su Z. The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses. Can Urol Assoc J. 2013;7(3-4):E161-167. doi: 10.5489/cuaj.477.
- Corona G., Tirabassi G., Santi D., Maseroli E., Gacci M., Dicuio M., Sforza A., Mannucci E., Maggi М. Sexual dysfunction in subjects treated with inhibitors of 5a-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671-678. Doi: 10.1111/ andr.12353.
Supplementary files
